INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease with signifi cant extrapulmonary effects that may contribute to the severity in individual patients. COPD has been projected to become the fourth leading cause of death worldwide in 2030. The extrapulmonary comorbidities infl uence the prognosis of the patients with COPD. 1 Type 2 diabetes mellitus (DM) is common in patients with COPD. According to the available studies the prevalence of DM in COPD patients varies between 2-37%. 2 Available studies suggest that DM may have impact on quality of life 3 and lung function [4] [5] [6] [7] [8] [9] in COPD patients. However, some studies found no association between lung function and the presence of DM. [10] [11] [12] There are not enough data to determine whether the results from these studies are applicable to specifi c subgroups of patients such as COPD patients admitted for exacerbation.
AIM
The aim of this study was to examine correlations between DM and quality of life and lung function in patients with COPD admitted for exacerbation.
PATIENTS AND METHODS
A total of 152 COPD patients hospitalized for exacerbation were studied for the presence of DM and prediabetes using well-established criteria for:
• Presence of DM: fasting plasma glucose ≥ 7.0 mmol/L or 2-h plasma glucose ≥ 11.1 mmol/L during an oral glucose tolerance test (OGTT) or HbA1c ≥ 6.5% or on therapy. 13 • Presence of prediabetes: fasting plasma glucose 5.6-6.9 mmol/L or 2-h plasma glucose 7.8-11.0 mmol/L during an OGTT or HbA1c ≥ 5.7-6.4% 13 Folia Medica I 2016 I Vol. 58 I No. 1 I Article 5
The diagnosis of COPD was made according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria. 1 Data were gathered for age, sex, therapy for DM and COPD therapy. The patients completed CAT and mMRC questionnaires and underwent pre-and post-bronchodilator spirometry.
The inclusion criteria were post-bronchodilator spirometry obstruction defi ned as FEV1/FVC < 0.70. All participants in this study signed informed consent.
The exclusion criteria were failure to comply with study procedures (no completed questionnaires, no medical and demographic information, no spirometry, no lab tests) or FEV1/FVC ratio > 0.70 after administration of bronchodilator.
QUALITY OF LIFE
Quality of life was assessed with the mMRC scale and CAT questionnaire. Patients were instructed that there were no right or wrong answers. All patients' questions were answered. Patients were classifi ed according to GOLD as having less symptoms (CAT < 10) and breathlessness (mMRC grade 0-1) and more symptoms (CAT ≥ 10) and breathlessness (mMRC grade ≥ 2). Because all patients were hospitalized for exacerbation there were only group C (high risk, less symptoms) and group D (high risk, more symptoms) patients according to GOLD. 1 
PULMONARY FUNCTION TESTING
The spirometry was performed using Minispir® New spirometer (MIR -Medical International Research, Italy). Patients were instructed to withdraw using short-acting β2-agonists at least 6 hours, long-acting β2-agonist at least 12 hours, long acting muscarinic antagonist 24 hours and short acting muscarinic antagonist 12 hours before the spirometry. 14 Postbronchodilator spirometry testing was performed 15-30 min after inhalation of 400 mcg salbutamol according to ERS/ATS recommendations. 14 Patients' obstruction were classifi ed according to the severity of airfl ow limitation based on postbronchodilator FEV1 as follows: mild (≥ 80% predicted); moderate (80 > FEV1 ≥ 50% predicted); severe (50% > FEV1 ≥ 30% predicted); very severe (< 30% predicted). 1 
BLOOD SAMPLES AND ANALYSES
A venous blood sample was collected from each subject after 12-hour fasting. Blood samples were taken as late as possible before discharging (usually on days 6 or 7). Plasma glucose was measured with a Roche COBAS INTEGRA® 400 plus analyzer and an enzymatic reference method with hexokinase. Glycated hemoglobin (HbA1c) was measured with a NycoCard device and boronate affi nity assay. For patients without established DM a 75g OGTT was performed with blood samples for glucose taken at 1 and 2 hours.
STATISTICAL ANALYSIS
Statistical analysis was performed with SPSS for Windows, v. 22.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were presented as mean ± standard deviation and 95 confi dence intervals (95% CI) and categorical variables -as percentages. Chi-square test was used to determine the associations between categorical variables. Continuous variables were examined for normality by Shapiro-Wilk test. For normally distributed variables, differences between the groups were determined by independent-samples t-test for two samples and analysis of variance (ANOVA) for more than 2 samples. Mann-Whitney U test was used for abnormally distributed variables with 2 samples and Kruskal-Wallis test for variables with more than 2 samples. Signifi cance value (pvalue) was set at 0.05.
All patients signed informed consent. Medical University-Sofi a Research Ethics Commission approved the study.
RESULTS

CHARACTERISTICS OF PATIENTS
A total of 152 COPD patients admitted for exacerbation were recruited from St. Sofi a University Hospital for Pulmonary Diseases, Sofi a, Bulgaria. Mean age of patients in this study was 65.1 ± 9.9 years. 71.1% (108/152) were males, 28.9% (44/152) were females; mean post-bronchodilator FEV 1 
QUALITY OF LIFE RESULTS
Our study did not fi nd difference between mMRC and CAT scores in relation to the presence of DM or prediabetes (Table 2) . Prevalence of DM was not signifi cantly different between patients with less symptoms (CAT 0-9) and breathlessness (mMRC 0 or 1) compared to patients with more symptoms (CAT ≥ 10) and breathlessness (mMRC ≥ 2) (all p > 0.05) ( Table 1) . However, all patients with untreated DM were in GOLD grade D, whereas 84.8% of the patients without DM were in GOLD grade D (p = 0.018).
Linear There is no difference in prevalence of DM in patients with FEV1 < 50%, when compared to patients with FEV1 > 50% (p = 0.659) or regarding GOLD stage (p = 0.861) ( Table 1) .
Linear regression analysis shows that HbA1c is a risk factor for lower FVC (R = 0.166, r 2 = 0.027, p = 0.041, B = -3.116, 95% CI -6.111-0.122). This is valid for males (R = 0.221, r 2 = 0.049, p = 0.022, B = -5.037, 95% CI -9.327-0.747) but not for females (p > 0.05).
DISCUSSION
Our study has not found difference between mMRC and CAT scores in relation to the presence of DM or prediabetes. Prevalence of DM is not signifi cantly different between patients with less symptoms (CAT 0-9) and breathlessness (mMRC 0 or 1) compared to patients with more symptoms (CAT ≥10) and breathlessness (mMRC ≥2). This is in contrast with the data about reduced quality of life in patients with DM 3 but may be explained with COPD having higher negative impact on quality of life than DM (physical limitation due to shortness of breath) 15 and ameliorating the effect in patients having the two diseases. Second, newly found DM which represents a signifi cant percentage in the DM group is unlikely to be associated with diabetic complications (for example painful neuropathy, retinopathy etc.) that have already been associated with a reduced quality of life, independent of the presence of COPD. However, all patients with untreated DM are in GOLD grade D, whereas 84.8% of the patients with untreated DM are in GOLD grade D which is statistically signifi cant.
This study shows HbA1c as a risk factor for reduced quality of life with strongest impact on the sixth CAT question -confi dence. HbA1c is a risk factor for reduced quality of life in males, but not in females measured with total CAT score.
In this study, presence of DM is not associated with reduced quality of life, whereas untreated DM is associated with worse quality of life. HbA1c shows weak positive correlation with CAT score. These results show the importance of screening for the disease and early treatment.
COPD is characterized by airway obstruction, which is not fully reversible. DM is associated with a reduction of lung volumes. 4, 5 Large epidemiological studies have found a correlation between lung volumes on one hand and duration of DM and the presence of complications on the other. [6] [7] [8] [9] It should be noted that some studies found no association between lung function and the presence of DM. [10] [11] [12] Our study did not fi nd differences in FVC, FEV1, FEV6, PEF, FEF2575 and FEV3 according to the presence of DM with FVC difference between the groups being almost signifi cant. There is no difference in the prevalence of DM in patients with FEV1 < 50%, when compared to patients with FEV1 > 50% or regarding GOLD stage. Prediabetes was not associated with impaired lung function.
However, untreated (new) DM is associated with signifi cantly lower FVC and FEV6 when compared to patients without DM. FVC is further decreased in males with untreated DM.
Linear regression shows higher HbA1c is a risk factor for lower FVC in males but not for females. DM in our study is not associated with deteriorated pulmonary function but untreated DM is associated with lower FVC and FEV6. The present study, which examines DM prevalence in COPD patients hospitalized for exacerbation, is not without some limitations. COPD exacerbation is an acute condition which may alter the glucose metabolism. However, all tests were performed at relatively stable condition (as late as possible before discharging). Secondly, the average dose of systemic steroid was 40 mg for 3 days, total 120 mg and subjects with DM usually receive only a single dose of 40 mg. Thirdly, lab tests were performed at least 48 hours after the last dose of systemic steroids. Also, 91% of patients with newly diagnosed diabetes had HbA1c ≥ 6.5% suggesting prolonged hyperglycemia (Table 4) .
CONCLUSIONS
This study has found high prevalence of DM (34.9%) in COPD patients. The presence of DM is not associated with reduced quality of life and worse pulmonary function. Untreated DM, however, is associated with worse quality of life and lung function which stresses the importance of screening for the disease. The patients may benefi t from optimizing their blood glucose levels.
